Corticotropin releasing factor (CRF) has a peripheral site of action for antinociception

Kenneth M. Hargreaves, Ronald Dubner, Ann H. Costello

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


In the rat carrageenan model of inflammation, systemically administered CRF significantly reduced hyperalgesia, edema and hyperthermia. While hypophysectomy had no effect, adrenalectomy blocked the effects of systemic CRF on edema and hyperthermia, and tended to reduce the peptide's ability to suppress hyperalgesia. When CRF was injected into one of two bilaterally inflamed hindpaws, it significantly inhibited hyperalgesia via a peripheral mechanism. In this model of inflammation, the antinociceptive effects of CRF are peripherally mediated, while the anti-inflammatory effects are dependent on the adrenal gland.

Original languageEnglish (US)
Pages (from-to)275-279
Number of pages5
JournalEuropean Journal of Pharmacology
Issue number3
StatePublished - Nov 7 1989
Externally publishedYes


  • Analgesia
  • Corticotropin releasing factor (CRF)
  • Hyperalgesia
  • Inflammation
  • Pain

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Corticotropin releasing factor (CRF) has a peripheral site of action for antinociception'. Together they form a unique fingerprint.

Cite this